Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1
The experimentally established mechanism targets of Niacinamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.73 |
| ▸ | F3 | P13726 | 1/20 | 0.73 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.73 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.73 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.73 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.73 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.73 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.73 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.55 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.50 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niacinamide SCHEMBL6698484 | 1.00 | F7 (0.73) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL2480073 | 0.90 | F7 (0.73) | F7F3SARM1SIRT2SIRT6 | |
| Cadaverine Tartrate SCHEMBL29103712 | 0.88 | F7 (0.76) | F7F3SARM1SIRT2SIRT6 | |
| Cadaverine Tartrate SCHEMBL27679158 | 0.88 | F7 (0.76) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL675207 | 0.88 | F7 (0.96) | F7F3SARM1SIRT2SIRT6 | |
| Niacin SCHEMBL811678 | 0.86 | ALDH1A1 (0.75) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL18443774 | 0.86 | F7 (0.85) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL28307211 | 0.86 | F7 (0.85) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL8462317 | 0.86 | F7 (0.67) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL27671762 | 0.86 | F7 (0.92) | F7F3SARM1SIRT2SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1053 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116236410-A | Ionic liquid cosmetic peptide stock solution and preparation method and application thereof | 武汉绿合医药科技有限公司 | 2023-06-09 | — | — | CN | claimed |
| US-20190142800-A1 | SYNERGISTIC ANTIFUNGAL COMPOSITIONS AND METHODS THEREOF | VYOME THERAPEUTICS LIMITED (IN) | 2019-05-16 | — | — | US | claimed |
| CN-109689034-A | Cooperate with antifungal composition and its method | 维奥梅治疗有限公司 | 2019-04-26 | — | — | CN | claimed |
| EP-3468544-A2 | SYNERGISTIC ANTIFUNGAL COMPOSITIONS AND METHODS THEREOF | Vyome Therapeutics Limited (IN) | 2019-04-17 | — | — | EP | claimed |
| WO-2017216722-A2 | SYNERGISTIC ANTIFUNGAL COMPOSITIONS AND METHODS THEREOF | VYOME BIOSCIENCES PVT. LTD. (IN) | 2017-12-21 | — | — | WO | claimed |
| US-20060147508-A1 | Concurrent Enhancement of Skin Penetration of Organic Base Active Agents and Organic Hydroxy Acid Active Agents as Their Ion-Pair Complexes | BIODERM RESEARCH (US) | 2006-07-06 | — | — | US | claimed |
| US-20040228884-A1 | Ion-pair delivery system for cosmetic and pharmaceutical compositions | GUPTA SHYAM K (US) | 2004-11-18 | — | — | US | claimed |
| US-20040156873-A1 | Topically Bioavailable Acne and Rosacea Treatment Compositions | GUPTA SHYAM K (US) | 2004-08-12 | — | — | US | claimed |
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | GUPTA SHYAM K (US) | 2004-05-13 | — | — | US | claimed |
| US-20040081672-A1 | Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging | GUPTA SHYAM K (US) | 2004-04-29 | — | — | US | claimed |
| CN-122055135-A | Cosmetic compositions and methods of use thereof | 玫琳凯有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-120129464-A | Flavonoid compound and application thereof | 弗门尼舍有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-120051283-A | Nutraceutical compositions and methods of use thereof | 玫琳凯有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-119604269-A | Composition for enhancing cooling effect | 弗门尼舍公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119365184-A | Topical compositions and methods of use thereof | 玫琳凯有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20040156873-A1 | Topically Bioavailable Acne and Rosacea Treatment Compositions | GUPTA SHYAM K (US) | 2004-08-12 | — | — | US | disclosed |
| US-20040146539-A1 | Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits | GUPTA SHYAM K (US) | 2004-07-29 | — | — | US | disclosed |
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | GUPTA SHYAM K (US) | 2004-05-13 | — | — | US | disclosed |
| US-20040081672-A1 | Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging | GUPTA SHYAM K (US) | 2004-04-29 | — | — | US | disclosed |
| US-4177141-A | PRE-IMPREGNATION | ISIZUKA HIROSI | 1979-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | CUTA, HIRA, HARS1 | HDAC1 3070/4885HDAC6 2477/4885F7 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.